101
Participants
Start Date
November 2, 2016
Primary Completion Date
March 19, 2020
Study Completion Date
May 31, 2023
Avalglucosidase alfa (GZ402666)
Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
Alglucosidase alfa (GZ419829)
Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
Investigational Site Number 0560003, Brussels
Investigational Site Number 3480001, Budapest
Investigational Site Number 0400001, Vienna
Investigational Site Number 2080003, København Ø
Investigational Site Number 0560001, Leuven
Investigational Site Number 0360001, Auchenflower
Investigational Site Number 7560002, Zurich
Investigational Site Number 1580001, Taipei
Investigational Site Number 3800003, Torino
Investigational Site Number 8400008, Valhalla
Investigational Site Number 8400026, Great Neck
Investigational Site Number 2030001, Prague
Investigational Site Number 2500006, Marseille
Investigational Site Number 8400025, Pittsburgh
Investigational Site Number 3800002, Milan
Investigational Site Number 8400005, Fairfax
Investigational Site Number 3800006, Brescia
Investigational Site Number 8400024, Morgantown
Investigational Site Number 8400006, Durham
Investigational Site Number 2500011, Brest
Investigational Site Number 8400007, Decatur
Investigational Site Number 8400016, Gainesville
Investigational Site Number 7920002, Istanbul
Investigational Site Number 2760006, Bochum
Investigational Site Number 2760002, Münster
Investigational Site Number 8400001, Detroit
Investigational Site Number 2500008, Angers
Investigational Site Number 8400002, Iowa City
Investigational Site Number 2760001, Mainz
Investigational Site Number 8400019, Minneapolis
Investigational Site Number 2500005, Lille
Investigational Site Number 8400023, Chicago
Investigational Site Number 2500010, Clermont-Ferrand
Investigational Site Number 2500004, Bron
Investigational Site Number 2500001, Paris
Investigational Site Number 3800007, Napoli
Investigational Site Number 2760003, München
Investigational Site Number 8400018, Salt Lake City
Investigational Site Number 8400015, Phoenix
Investigational Site Number 8400020, Los Angeles
Investigational Site Number 8400011, Orange
Investigational Site Number 8400017, Stanford
Investigational Site Number 8400014, Portland
Investigational Site Number 3800001, Messina
Investigational Site Number 6430001, Moscow
Investigational Site Number 8400012, Kansas City
Investigational Site Number 8400010, Boston
Investigational Site Number 8400009, Cincinnati
Investigational Site Number 0320001, Caba
Investigational Site Number 0760004, Brasília
Investigational Site Number 0760001, São Paulo
Investigational Site Number 1240003, Hamilton
Investigational Site Number 1240002, Montreal
Investigational Site Number 2500007, Bordeaux
Investigational Site Number 3920002, Kodaira-Shi
Investigational Site Number 4840001, México
Investigational Site Number 5280001, Rotterdam
Investigational Site Number 6160001, Warsaw
Investigational Site Number 6200001, Braga
Investigational Site Number 4100001, Seoul
Investigational Site Number 4100002, Seoul
Investigational Site Number 7240002, Barcelona
Investigational Site Number 7240003, Barcelona
Investigational Site Number 7920001, Ankara
Investigational Site Number 8260005, Birmingham
Investigational Site Number 8260002, Cambridge
Investigational Site Number 8260001, London
Investigational Site Number 8260004, Newcastle upon Tyne
Investigational Site Number 8260003, Salford
Genzyme, a Sanofi Company
INDUSTRY